drugset / Trial / NCT07480733
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label Phase II clinical study. The primary objective is to evaluate the investigator-assessed objective response rate of JS212 and JS213 as monotherapy and in combination regimens in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and preliminary efficacy of JS212, JS213, as well as JS212 in combination with JS213, toripalimab, and JS207.
Timeline
- Start
- 2026-04-23
- Primary completion
- 2027-11-30
- Completion
- 2028-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS207 | Monoclonal antibody | — | Intravenous |
| Subject | JS212 | Unknown | — | Intravenous |
| Subject | JS213 | Unknown | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |